Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
70 participants
INTERVENTIONAL
2018-01-04
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Losartan and Social Processing
NCT06624904
Effects of Intranasal Oxytocin on Fear Processing in Naturalistic Contexts
NCT05892939
Influence of Escitalopram on Fear Conditioning
NCT01398514
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
NCT06004115
Neurobiology of Generalized Fear-Conditioning & Avoidance in Anxiety Disorders
NCT03033056
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Losartan group
Losartan
administration of losartan (50 mg) (oral)
Placebo group
Placebo Oral Tablet
administration of placebo (oral)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Losartan
administration of losartan (50 mg) (oral)
Placebo Oral Tablet
administration of placebo (oral)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* medical or psychiatric illness
* hypertension
18 Years
30 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Electronic Science and Technology of China
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Benjamin Becker
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Benjamin Becker, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Electronic Science and Technology of China
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Electronic Science and Technology of China
Chengdu, Sichuan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Zhou F, Geng Y, Xin F, Li J, Feng P, Liu C, Zhao W, Feng T, Guastella AJ, Ebstein RP, Kendrick KM, Becker B. Human Extinction Learning Is Accelerated by an Angiotensin Antagonist via Ventromedial Prefrontal Cortex and Its Connections With Basolateral Amygdala. Biol Psychiatry. 2019 Dec 15;86(12):910-920. doi: 10.1016/j.biopsych.2019.07.007. Epub 2019 Jul 25.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UESTC-neuSCAN-25
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.